TD Cowen analyst Tyler Van Buren has maintained their bullish stance on JBIO stock, giving a Buy rating on May 7.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Tyler Van Buren has given his Buy rating due to a combination of factors that highlight Jade Biosciences’ promising future. The company’s lead asset, JADE101, is a potential best-in-class anti-APRIL monoclonal antibody with significantly higher potency and a longer dosing interval compared to existing treatments. This is supported by preclinical data that demonstrate JADE101’s ability to avoid the target-mediated drug disposition effect, which is a limitation for other anti-APRIL therapies.
Furthermore, Jade Biosciences is led by an experienced team with a successful track record, having previously sold a portfolio for a substantial amount. The upcoming Phase Ia trial in healthy volunteers is expected to provide key data on JADE101’s pharmacokinetics and pharmacodynamics, with the potential for extended dosing intervals. These factors, combined with the anticipated data readouts, contribute to the positive outlook and the Buy rating for Jade Biosciences.
In another report released on May 7, Wedbush also initiated coverage with a Buy rating on the stock with a $17.00 price target.